Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
venetoclax (100 mg on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg from days 4 to 14) with blinatumomab (9 to 28 ug/day) for 14 days
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The 14-day BV regimen induced rapid deep remission (91.7% MRD-negative by day 21) with manageable toxicity in Ph-negative B-ALL. Synergistic T-cell activation by venetoclax may explain enhanced efficacy.
[PURPOSE] This study evaluated the efficacy and safety of a 14-day blinatumomab-venetoclax (BV) regimen as induction therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia (B-ALL)
- 추적기간 283 days
APA
Lei Y, Zhao X, et al. (2025). Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia.. Blood and lymphatic cancer : targets and therapy, 15, 193-202. https://doi.org/10.2147/BLCTT.S556608
MLA
Lei Y, et al.. "Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia.." Blood and lymphatic cancer : targets and therapy, vol. 15, 2025, pp. 193-202.
PMID
41216208 ↗
Abstract 한글 요약
[PURPOSE] This study evaluated the efficacy and safety of a 14-day blinatumomab-venetoclax (BV) regimen as induction therapy for newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia (B-ALL), focusing on rapid remission and tolerability in unfit patients.
[PATIENTS AND METHODS] Thirteen patients received venetoclax (100 mg on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg from days 4 to 14) with blinatumomab (9 to 28 ug/day) for 14 days. Bone marrow assessments were performed at days 14-21. Primary endpoints were complete remission (CR) rate, minimal residual disease (MRD) negativity by flow cytometry, and adverse events.
[RESULTS] The CR rate after one cycle of BV regimen was 92.3% (12/13), and all patients achieved MRD-negativity; 91.7% (11/12) achieved MRD clearance by day 21. Grade 1-2 cytokine release syndrome occurred in 46.2% (6/13; 1 grade 3). Hematologic toxicity included grade 3-4 neutropenia (92.3%) and thrombocytopenia (46.2%), with only 30.8% febrile neutropenia. All AEs resolved rapidly with supportive care, allowing therapy to continue without interruption. At median follow-up of 283 days, 1-year relapse-free survival rate and overall survival rate were 60.6% and 83.3%.
[CONCLUSION] The 14-day BV regimen induced rapid deep remission (91.7% MRD-negative by day 21) with manageable toxicity in Ph-negative B-ALL. Synergistic T-cell activation by venetoclax may explain enhanced efficacy.
[PATIENTS AND METHODS] Thirteen patients received venetoclax (100 mg on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg from days 4 to 14) with blinatumomab (9 to 28 ug/day) for 14 days. Bone marrow assessments were performed at days 14-21. Primary endpoints were complete remission (CR) rate, minimal residual disease (MRD) negativity by flow cytometry, and adverse events.
[RESULTS] The CR rate after one cycle of BV regimen was 92.3% (12/13), and all patients achieved MRD-negativity; 91.7% (11/12) achieved MRD clearance by day 21. Grade 1-2 cytokine release syndrome occurred in 46.2% (6/13; 1 grade 3). Hematologic toxicity included grade 3-4 neutropenia (92.3%) and thrombocytopenia (46.2%), with only 30.8% febrile neutropenia. All AEs resolved rapidly with supportive care, allowing therapy to continue without interruption. At median follow-up of 283 days, 1-year relapse-free survival rate and overall survival rate were 60.6% and 83.3%.
[CONCLUSION] The 14-day BV regimen induced rapid deep remission (91.7% MRD-negative by day 21) with manageable toxicity in Ph-negative B-ALL. Synergistic T-cell activation by venetoclax may explain enhanced efficacy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Conventional papillary thyroid carcinoma with intraglandular lymphatic dissemination shows more aggressive features.
- Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier.
- WDR5-H3K4me3 Epigenetic Axis Promotes TRMT6-Dependent tRNA MA Modification to Facilitate Triple-Negative Breast Cancer Progression by Suppressing Ferroptosis.
- CXCR5 monocyte emigration impairs the radiation-induced antitumor immune response.
- A Neuraminidase-Functionalized Injectable Hydrogel Depletes Sialic Acid to Disrupt the Tumor-Osteoclast Cycle and Suppress Breast Cancer Bone Metastasis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.
- [Rapid determination of venetoclax in plasma by ultra performance liquid chromatography-tandem mass spectrometry].
- Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience.
- [Simultaneous determination of selinexor， posaconazole， venetoclax， and voriconazole in human plasma using ultra-high performance liquid chromatography-tandem mass spectrometry].